Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Raptor Pharmaceutical
September 20, 2016
Allergan sparks a second liver disease craze
September 14, 2016
Vitae buyout marks another comedown for exuberant biotech bulls
September 12, 2016
Raptor faces up to its new reality
August 03, 2016
Therapy focus – One step forward but two steps back in Huntington’s
April 15, 2016
Upcoming events – Phase II data for Raptor and The Medicines Company
August 13, 2015
Upcoming events: Intra-Cellular and Raptor target unmet CNS needs
August 12, 2014
Intercept soars again as safety fears fade
March 17, 2014
Raptor picks a bad week to bury bad news
February 21, 2014
Glimmers of hope in Huntington's must not be overstated
June 20, 2013
Upcoming events: Alnylam and Biogen readouts plus decision time at the CHMP meeting
May 01, 2013
After Procysbi approval the pricing battle begins
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 17, 2019
Vantage 2020 Preview
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Editor's Picks
January 09, 2020
What makes a great year for takeovers?
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
December 19, 2019
Gene therapy clinical holds take centre stage
December 20, 2019
Plenty of choice remains for buyers of gene therapy
October 14, 2019
Uncovering biopharma’s hidden treasures
